File Download
  • No File Attached
 
Links for fulltext
(May Require Subscription)
 
Supplementary

Article: Effect of esomeprazole versus famotidine on platelet inhibition by clopidogrel: A double-blind, randomized trial
  • Basic View
  • Metadata View
  • XML View
TitleEffect of esomeprazole versus famotidine on platelet inhibition by clopidogrel: A double-blind, randomized trial
 
AuthorsTunggal, P2
Ng, FH2
Lam, KF1
Chan, FKL3
Lau, YK2
 
Issue Date2011
 
PublisherMosby, Inc. The Journal's web site is located at http://www.elsevier.com/locate/ahj
 
CitationAmerican Heart Journal, 2011, v. 162 n. 5, p. 870-874 [How to Cite?]
DOI: http://dx.doi.org/10.1016/j.ahj.2011.08.007
 
AbstractBackground: Previous studies showed that esomeprazole does not interfere significantly with the platelet inhibitory effect of clopidogrel. It is unknown whether famotidine, a histamine 2 receptor antagonist, interacts with clopidogrel. This double-blind, randomized study aimed to compare the influence of esomeprazole and famotidine on the platelet inhibitory effect of clopidogrel. Methods: Patients with acute coronary syndrome or elective percutaneous coronary interventions treated with aspirin and clopidogrel cotherapy were randomized to receive esomeprazole 20 mg daily or famotidine 40 mg daily. Platelet reactivity units (PRUs) were measured at baseline and on day 28. The primary analysis involved the PRU values on day 28. Results: There were 44 patients in the esomeprazole group and 44 in the famotidine group. The baseline PRUs of the 2 groups were comparable (esomeprazole vs famotidine, 229.1 ± 85.6 vs 220.4 ± 83.0, P =.63). The PRUs on day 28 were 242.6 ± 89.7 and 237.5 ± 79.2 in the groups receiving esomeprazole and famotidine, respectively (mean difference 5.1, 95% CI -30.8 to 41.0, P =.78). Conclusions: The platelet inhibitory effect of clopidogrel was not significantly different between patients receiving esomeprazole and those receiving famotidine. Neither esomeprazole nor famotidine reduced the platelet inhibitory effect of clopidogrel. © 2011 Mosby, Inc. All rights reserved.
 
ISSN0002-8703
2013 Impact Factor: 4.555
 
DOIhttp://dx.doi.org/10.1016/j.ahj.2011.08.007
 
ReferencesReferences in Scopus
 
DC FieldValue
dc.contributor.authorTunggal, P
 
dc.contributor.authorNg, FH
 
dc.contributor.authorLam, KF
 
dc.contributor.authorChan, FKL
 
dc.contributor.authorLau, YK
 
dc.date.accessioned2012-08-16T05:59:13Z
 
dc.date.available2012-08-16T05:59:13Z
 
dc.date.issued2011
 
dc.description.abstractBackground: Previous studies showed that esomeprazole does not interfere significantly with the platelet inhibitory effect of clopidogrel. It is unknown whether famotidine, a histamine 2 receptor antagonist, interacts with clopidogrel. This double-blind, randomized study aimed to compare the influence of esomeprazole and famotidine on the platelet inhibitory effect of clopidogrel. Methods: Patients with acute coronary syndrome or elective percutaneous coronary interventions treated with aspirin and clopidogrel cotherapy were randomized to receive esomeprazole 20 mg daily or famotidine 40 mg daily. Platelet reactivity units (PRUs) were measured at baseline and on day 28. The primary analysis involved the PRU values on day 28. Results: There were 44 patients in the esomeprazole group and 44 in the famotidine group. The baseline PRUs of the 2 groups were comparable (esomeprazole vs famotidine, 229.1 ± 85.6 vs 220.4 ± 83.0, P =.63). The PRUs on day 28 were 242.6 ± 89.7 and 237.5 ± 79.2 in the groups receiving esomeprazole and famotidine, respectively (mean difference 5.1, 95% CI -30.8 to 41.0, P =.78). Conclusions: The platelet inhibitory effect of clopidogrel was not significantly different between patients receiving esomeprazole and those receiving famotidine. Neither esomeprazole nor famotidine reduced the platelet inhibitory effect of clopidogrel. © 2011 Mosby, Inc. All rights reserved.
 
dc.description.natureLink_to_subscribed_fulltext
 
dc.identifier.citationAmerican Heart Journal, 2011, v. 162 n. 5, p. 870-874 [How to Cite?]
DOI: http://dx.doi.org/10.1016/j.ahj.2011.08.007
 
dc.identifier.doihttp://dx.doi.org/10.1016/j.ahj.2011.08.007
 
dc.identifier.epage874
 
dc.identifier.hkuros205610
 
dc.identifier.issn0002-8703
2013 Impact Factor: 4.555
 
dc.identifier.issue5
 
dc.identifier.pmid22093203
 
dc.identifier.scopuseid_2-s2.0-81255214744
 
dc.identifier.spage870
 
dc.identifier.urihttp://hdl.handle.net/10722/159913
 
dc.identifier.volume162
 
dc.languageeng
 
dc.publisherMosby, Inc. The Journal's web site is located at http://www.elsevier.com/locate/ahj
 
dc.publisher.placeUnited States
 
dc.relation.ispartofAmerican Heart Journal
 
dc.relation.referencesReferences in Scopus
 
dc.subject.meshAcute Coronary Syndrome - blood - drug therapy
 
dc.subject.meshAnti-Ulcer Agents - administration and dosage
 
dc.subject.meshFamotidine - administration and dosage
 
dc.subject.meshOmeprazole - administration and dosage
 
dc.subject.meshPlatelet Aggregation Inhibitors - administration and dosage
 
dc.titleEffect of esomeprazole versus famotidine on platelet inhibition by clopidogrel: A double-blind, randomized trial
 
dc.typeArticle
 
<?xml encoding="utf-8" version="1.0"?>
<item><contributor.author>Tunggal, P</contributor.author>
<contributor.author>Ng, FH</contributor.author>
<contributor.author>Lam, KF</contributor.author>
<contributor.author>Chan, FKL</contributor.author>
<contributor.author>Lau, YK</contributor.author>
<date.accessioned>2012-08-16T05:59:13Z</date.accessioned>
<date.available>2012-08-16T05:59:13Z</date.available>
<date.issued>2011</date.issued>
<identifier.citation>American Heart Journal, 2011, v. 162 n. 5, p. 870-874</identifier.citation>
<identifier.issn>0002-8703</identifier.issn>
<identifier.uri>http://hdl.handle.net/10722/159913</identifier.uri>
<description.abstract>Background: Previous studies showed that esomeprazole does not interfere significantly with the platelet inhibitory effect of clopidogrel. It is unknown whether famotidine, a histamine 2 receptor antagonist, interacts with clopidogrel. This double-blind, randomized study aimed to compare the influence of esomeprazole and famotidine on the platelet inhibitory effect of clopidogrel. Methods: Patients with acute coronary syndrome or elective percutaneous coronary interventions treated with aspirin and clopidogrel cotherapy were randomized to receive esomeprazole 20 mg daily or famotidine 40 mg daily. Platelet reactivity units (PRUs) were measured at baseline and on day 28. The primary analysis involved the PRU values on day 28. Results: There were 44 patients in the esomeprazole group and 44 in the famotidine group. The baseline PRUs of the 2 groups were comparable (esomeprazole vs famotidine, 229.1 &#177; 85.6 vs 220.4 &#177; 83.0, P =.63). The PRUs on day 28 were 242.6 &#177; 89.7 and 237.5 &#177; 79.2 in the groups receiving esomeprazole and famotidine, respectively (mean difference 5.1, 95% CI -30.8 to 41.0, P =.78). Conclusions: The platelet inhibitory effect of clopidogrel was not significantly different between patients receiving esomeprazole and those receiving famotidine. Neither esomeprazole nor famotidine reduced the platelet inhibitory effect of clopidogrel. &#169; 2011 Mosby, Inc. All rights reserved.</description.abstract>
<language>eng</language>
<publisher>Mosby, Inc. The Journal&apos;s web site is located at http://www.elsevier.com/locate/ahj</publisher>
<relation.ispartof>American Heart Journal</relation.ispartof>
<subject.mesh>Acute Coronary Syndrome - blood - drug therapy</subject.mesh>
<subject.mesh>Anti-Ulcer Agents - administration and dosage</subject.mesh>
<subject.mesh>Famotidine - administration and dosage</subject.mesh>
<subject.mesh>Omeprazole - administration and dosage</subject.mesh>
<subject.mesh>Platelet Aggregation Inhibitors - administration and dosage</subject.mesh>
<title>Effect of esomeprazole versus famotidine on platelet inhibition by clopidogrel: A double-blind, randomized trial</title>
<type>Article</type>
<description.nature>Link_to_subscribed_fulltext</description.nature>
<identifier.doi>10.1016/j.ahj.2011.08.007</identifier.doi>
<identifier.pmid>22093203</identifier.pmid>
<identifier.scopus>eid_2-s2.0-81255214744</identifier.scopus>
<identifier.hkuros>205610</identifier.hkuros>
<relation.references>http://www.scopus.com/mlt/select.url?eid=2-s2.0-81255214744&amp;selection=ref&amp;src=s&amp;origin=recordpage</relation.references>
<identifier.volume>162</identifier.volume>
<identifier.issue>5</identifier.issue>
<identifier.spage>870</identifier.spage>
<identifier.epage>874</identifier.epage>
<publisher.place>United States</publisher.place>
</item>
Author Affiliations
  1. The University of Hong Kong
  2. Ruttonjee Hospital Hong Kong
  3. Chinese University of Hong Kong